0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Cell > HGF R > SCCHO-ATP141

CHO/Human c-MET Stable Cell Line Development Service

Order Now

  • Description
    The CHO/Human c-MET Stable Cell Line was engineered to express the receptor full length human c-MET (Gene ID: 4233), used to mimic cancer target cells. Surface expression of human c-MET was confirmed by flow cytometry.
  • Application

    • Useful for cell-based c-MET binding assay

  • Growth Properties
    Adherent
  • Selection Marker
    Puromycin (2 μg/mL)
  • Culture Medium
    F-12K + 10% FBS
  • Freeze Medium
    Serum-free cell cryopreservation medium
  • Quantity
    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.
Receptor Assay
 HGF R FACS

Expression analysis of human c-MET on CHO/Human c-MET Stable Cell Line by FACS.
Cell surface staining was performed on CHO/Human c-MET Stable Cell Line or negative control cell using PE-labeled anti-human c-MET antibody.

Please contact us if you are interested in related cell pool service.

  • Background
    Hepatocyte growth factor receptor (HGFR) is also known as mesenchymal-epithelial transition factor (MET), c-Met, and is a glycosylated receptor tyrosine kinase that plays a central role in epithelial morphogenesis and cancer development. HGFR protein possesses tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. HGFR is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymal origin. Upon HGF stimulation, HGFR induces several biological responses that collectively give rise to a program known as invasive growth. Abnormal HGFR activation in cancer correlates with poor prognosis, where aberrantly active HGFR triggers tumor growth, formation of new blood vessels (angiogenesis) that supply the tumor with nutrients, and cancer spread to other organs (metastasis). HGFR is deregulated in many types of human malignancies, including cancers of kidney, liver, stomach, breast, and brain. Normally, only stem cells and progenitor cells express HGFR, However, cancer stem cells are thought to hijack the ability of normal stem cells to express HGFR, and thus become the cause of cancer persistence and spread to other sites in the body. Various mutations in the HGFR gene are associated with papillary renal carcinoma. HGFR mediates a complex program known as invasive growth. Activation of HGFR triggers mitogenesis, and morphogenesis.
  • Permits & Restrictions
    This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
  • Clinical and Translational Updates

Comments (0)


ETA des produits en stock: 2 jours ouvrables

Price(EUR) : €3540.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:9 Details
  • Number of Drugs in Clinical Trials:61 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop

Laisser un message